No insider purchase over the last 90 days. The latest, by LIU YONG, was filed 05 May 2026.
This page follows insider dealings at Jiangsu Recbio Technology Co., Ltd. - B as filed with HKEX, a company from the Technology sector. The last twelve months, up to 23 October 2026, brought 5 filings signed by 3 insiders.
The record shows 2 purchases on the open market, made by 2 insiders, against 3 sales by 3 insiders. No amount is published for 5 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 senior executives among the declarants.
With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,315 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 2 purchases and 3 sales.
The clock since the last published purchase (5 May 2026) now reads 173 days. Typically, a trade is published a median of 6 days after it takes place. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Hanza AB and Lime Technologies AB (publ). Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
5 of 5 declarations
Jiangsu Recbio Technology Co., Ltd. is a company focused on the development of biopharmaceutical technologies. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Purchases our model currently ranks for the recommendations list.
All recommendations